Aeterna Zentaris (AEZS) Misses Q3 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
UPDATE: Canaccord Genuity Upgrades AEterna Zentaris (AEZS) to Spec. Buy; Analyst Notes Removal of Dilution Overhang From Series B Warrants
November 9, 2015 6:42 AM EST(Updated - November 9, 2015 10:49 AM EST)
Canaccord Genuity upgraded Æterna Zentaris (NASDAQ: AEZS) from Hold to Spec. Buy with a price target of $0.10. Analyst Neil Maruoka said the agreement to exercise the majority of the Series B warrants substantially removes the single largest overhang for the stock. He also thinks Zoptrex pivotal data before the end of 2016 will major catalyst for the stock.
Maruoka explained, "Since Æterna Zentaris last reporting date, its stock price has continued to decline, losing ~66% of its value at the most recent closing price of US$0.057. We... More
